» Articles » PMID: 36981958

The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series

Overview
Publisher MDPI
Date 2023 Mar 29
PMID 36981958
Authors
Affiliations
Soon will be listed here.
Abstract

The treatment and interdisciplinary management of patients with chronic kidney disease (CKD) continue to improve long-term outcomes. The medical nutrition intervention's role is to establish a healthy diet plan for kidney protection, reach blood pressure and blood glucose goals, and prevent or delay health problems caused by kidney disease. Our study aims to report the effects of medical nutrition therapy-substituting foods rich in phosphorus-containing additives with ones low in phosphates content on phosphatemia and phosphate binders drug prescription in stage 5 CKD patients with hemodialysis. Thus, 18 adults with high phosphatemia levels (over 5.5 mg/dL) were monitored at a single center. Everyone received standard personalized diets to replace processed foods with phosphorus additives according to their comorbidities and treatment with prosphate binder drugs. Clinical laboratory data, including dialysis protocol, calcemia, and phosphatemia, were evaluated at the beginning of the study, after 30 and 60 days. A food survey was assessed at baseline and after 60 days. The results did not show significant differences between serum phosphate levels between the first and second measurements; thus, the phosphate binders' initial doses did not change. After 2 months, phosphate levels decreased considerably (from 7.322 mg/dL to 5.368 mg/dL); therefore, phosphate binder doses were diminished. In conclusion, medical nutrition intervention in patients with hemodialysis significantly reduced serum phosphate concentrations after 60 days. Restricting the intake of processed foods containing phosphorus additives-in particularized diets adapted to each patient's comorbidities-and receiving phosphate binders represented substantial steps to decrease phosphatemia levels. The best results were significantly associated with life expectancy; at the same time, they showed a negative correlation with the dialysis period and participants' age.

Citing Articles

Socio-Demographic Factors, Behaviors, Motivations, and Attitudes in Food Waste Management of Romanian Households.

Morosan E, Daraban A, Popovici V, Rusu A, Ilie E, Licu M Nutrients. 2024; 16(16).

PMID: 39203874 PMC: 11356938. DOI: 10.3390/nu16162738.


Industrial Use of Phosphate Food Additives: A Mechanism Linking Ultra-Processed Food Intake to Cardiorenal Disease Risk?.

Calvo M, Dunford E, Uribarri J Nutrients. 2023; 15(16).

PMID: 37630701 PMC: 10459924. DOI: 10.3390/nu15163510.


Current Technologies for Managing Type 1 Diabetes Mellitus and Their Impact on Quality of Life-A Narrative Review.

Elian V, Popovici V, Ozon E, Musuc A, Fita A, Rusu E Life (Basel). 2023; 13(8).

PMID: 37629520 PMC: 10456000. DOI: 10.3390/life13081663.

References
1.
Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

2.
Disthabanchong S . Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification. Int J Nephrol. 2018; 2018:3162806. PMC: 5911324. DOI: 10.1155/2018/3162806. View

3.
Abu-Zidan F, Abbas A, Hefny A . Clinical "case series": a concept analysis. Afr Health Sci. 2013; 12(4):557-62. PMC: 3598300. View

4.
Cannata-Andia J, Martin K . The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2015; 31(4):541-7. DOI: 10.1093/ndt/gfv055. View

5.
Deira J, Murea M, Kalantar-Zadeh K, Casino F, Basile C . Does delivering more dialysis improve clinical outcomes? What randomized controlled trials have shown. J Nephrol. 2022; 35(5):1315-1327. DOI: 10.1007/s40620-022-01246-8. View